Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients

Publisher Website
Google Scholar
Abstract
Aims Glibenclamide attenuates the protective responses to opening of vascular ATP‐sensitive potassium (KATP) channels during ischaemia. Therefore, glibenclamide treatment of Type 2 diabetes mellitus may have hazardous cardiovascular effects when used under conditions of ischaemia. Glimepiride and metformin seem to lack such characteristics. Based on these data, we hypothesized that, in contrast to glibenclamide, chronic treatment of Type 2 diabetic patients with glimepiride or metformin will not impair the vasodilator function of KATP opening in vivo. Methods Two groups of 12 Type 2 diabetes mellitus patients participated in a double‐blind randomized cross‐over study consisting of two 8‐week periods, in which treatment with orally administered glibenclamide (15 mg/day) was compared with either glimepiride or metformin (6 mg and 1500 mg/day, respectively). At the end of each treatment period, the increase in forearm blood flow (FBF, venous occlusion plethysmography) in response to intra‐arterial administered diazoxide (KATP opener), acetylcholine (endothelium‐dependent vasodilator) and dipyridamole (adenosine‐uptake blocker) and to forearm ischaemia was measured. Results There were no significant differences in vasodilator responses to diazoxide, acetylcholine, dipyridamole and forearm ischaemia after glibenclamide compared with glimepiride and metformin. Conclusions Chronic treatment of Type 2 diabetes mellitus with glimepiride or metformin has similar effects on vascular KATP channels compared with chronic glibenclamide treatment. Diabet. Med. 19, 136–143 (2002)